

Simon J C Davies

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7226671/publications.pdf>

Version: 2024-02-01

80
papers

2,968
citations

201385

27
h-index

168136

53
g-index

84
all docs

84
docs citations

84
times ranked

4235
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: A population-based cohort study. <i>Journal of Psychopharmacology</i> , 2022, 36, 460-469.	2.0	11
2	The Rationale and Design of Behavioral Interventions for Management of Agitation in Dementia in a Multi-Site Clinical Trial. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 827-840.	1.2	1
3	Impact of standardizing care for agitation in dementia using an integrated care pathway on an inpatient geriatric psychiatry unit. <i>International Psychogeriatrics</i> , 2022, 34, 919-928.	0.6	3
4	The impact of psychiatric and medical comorbidity on the risk of mortality: a population-based analysis. <i>Psychological Medicine</i> , 2021, 51, 320-328.	2.7	7
5	Anxiolytics: Misuse, Dependence, and Withdrawal Syndromes. , 2021, , 1-26.		0
6	Stability of extemporaneously compounded amiloride nasal spray. <i>PLoS ONE</i> , 2020, 15, e0232435.	1.1	10
7	Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial. <i>Journal of Psychopharmacology</i> , 2020, 34, 1342-1349.	2.0	2
8	Psychotropic Drug Treatment in Later Life. , 2020, , 543-576.		0
9	Plus Ça change? Benzodiazepine prescription in older patients with schizophrenia is common but best avoided. <i>International Psychogeriatrics</i> , 2020, 32, 419-422.	0.6	0
10	Antipsychotic Polypharmacy and Metabolic Syndrome in Schizophrenia: A Review of Systematic Reviews. <i>Focus (American Psychiatric Publishing)</i> , 2020, 18, 482-492.	0.4	5
11	Benzodiazepines versus placebo for panic disorder in adults. <i>The Cochrane Library</i> , 2019, 3, CD010677.	1.5	25
12	Does maternal somatic anxiety in pregnancy predispose children to hyperactivity?. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 1475-1486.	2.8	9
13	Antidepressants for major depression disorder in older people: a network meta-analysis. <i>The Cochrane Library</i> , 2019, , .	1.5	5
14	Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 690-703.	1.1	61
15	Anxiety disorder treatment guidelines: Little by little a consensus emerges. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 80-81.	1.3	1
16	Benzodiazepine prescription in Ontario residents aged 65 and over: a population-based study from 1998 to 2013. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 99-114.	1.2	17
17	Sequential drug treatment algorithm for agitation and aggression in Alzheimer's™s and mixed dementia. <i>Journal of Psychopharmacology</i> , 2018, 32, 509-523.	2.0	79
18	Using sedatives"hypnotics or opioids in older adults: a narrow path. <i>International Psychogeriatrics</i> , 2018, 30, 925-927.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). <i>BMJ: British Medical Journal</i> , 2018, 363, k4218.	2.4	44
20	Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. <i>BMC Psychiatry</i> , 2018, 18, 275.	1.1	60
21	Do mothers who are anxious during pregnancy have inattentive children?. <i>Journal of Affective Disorders</i> , 2018, 236, 120-126.	2.0	8
22	Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-136.	1.3	21
23	Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. <i>Canadian Family Physician</i> , 2018, 64, 339-351.	0.1	113
24	Management of panic disorder in primary care. <i>The Prescriber</i> , 2017, 28, 19-26.	0.1	0
25	Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. <i>The Cochrane Library</i> , 2017, , .	1.5	3
26	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 162-214.	1.3	226
27	Symptoms of generalized anxiety disorder but not panic disorder at age 15 years increase the risk of depression at 18 years in the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort study. <i>Psychological Medicine</i> , 2016, 46, 73-85.	2.7	21
28	Potential for Drug-Drug Interactions with Adjunctive Tramadol Use in Treatment of Obsessive-Compulsive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 308-309.	0.9	3
29	Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 66.	0.7	10
30	SSRI+antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. <i>Human Psychopharmacology</i> , 2016, 31, 252-255.	0.7	9
31	Individual oral symptoms in burning mouth syndrome may be associated differentially with depression and anxiety. <i>Acta Odontologica Scandinavica</i> , 2016, 74, 155-160.	0.9	29
32	The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1161-1168.	1.6	14
33	Treatment: special conditions. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 150-153.	2.3	0
34	Evidence for serotonin function as a neurochemical difference between fear and anxiety disorders in humans?. <i>Journal of Psychopharmacology</i> , 2015, 29, 1061-1069.	2.0	21
35	Prediction of Working Memory Performance in Schizophrenia by Plasma Ratio of Clozapine to <i>N</i> -Desmethylclozapine. <i>American Journal of Psychiatry</i> , 2015, 172, 579-585.	4.0	63
36	The Impact of Aging, Cognition, and Symptoms on Functional Competence in Individuals With Schizophrenia Across the Lifespan. <i>Schizophrenia Bulletin</i> , 2015, 41, 374-381.	2.3	55

#	ARTICLE	IF	CITATIONS
37	The pharmacological management of anxiety disorders. Progress in Neurology and Psychiatry, 2014, 18, 27-32.	0.4	4
38	Response to Damkier. British Journal of Clinical Pharmacology, 2014, 77, 1084-1085.	1.1	0
39	Methylphenidate use in pregnancy and lactation: a systematic review of evidence. British Journal of Clinical Pharmacology, 2014, 77, 96-101.	1.1	36
40	Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study. Comprehensive Psychiatry, 2014, 55, 1069-1076.	1.5	4
41	Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2014, 28, 403-439.	2.0	511
42	Benzodiazepines: Risks and benefits. A reconsideration. Journal of Psychopharmacology, 2013, 27, 967-971.	2.0	177
43	Agomelatine versus other antidepressive agents for major depression. The Cochrane Library, 2013, , CD008851.	1.5	51
44	Anxiety and Cardiovascular Disease. Modern Problems of Pharmacopsychiatry, 2013, 29, 85-97.	2.5	20
45	A U-shaped relationship between systolic blood pressure and panic symptoms: the HUNT study. Psychological Medicine, 2012, 42, 1969-1976.	2.7	14
46	Elucidation of neurobiology of anxiety disorders in children through pharmacological challenge tests and cortisol measurements: a systematic review. Journal of Psychopharmacology, 2012, 26, 431-442.	2.0	13
47	Psychotropic drugs. , 2012, , 311-348.		3
48	Cyproterone to treat aggressivity in dementia: a clinical case and systematic review. Journal of Psychopharmacology, 2011, 25, 141-145.	2.0	9
49	Panic disorder and subthreshold panic in the UK general population: Epidemiology, comorbidity and functional limitation. European Psychiatry, 2011, 26, 354-362.	0.1	39
50	Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. Psychopharmacology, 2010, 208, 223-232.	1.5	18
51	Characterisation of zuclopenthixol metabolism by <i>in vitro</i> and therapeutic drug monitoring studies. Acta Psychiatrica Scandinavica, 2010, 122, 444-453.	2.2	172
52	Severe Laryngeal Dystonia in a Patient Receiving Zuclopenthixol and Fluoxetine. Australasian Psychiatry, 2010, 18, 174-176.	0.4	10
53	Anxiety - bridging the heart/mind divide. Journal of Psychopharmacology, 2010, 24, 633-638.	2.0	20
54	Increased serum free tryptophan in patients with diarrhea-predominant irritable bowel syndrome. Nutrition Research, 2010, 30, 678-688.	1.3	35

#	ARTICLE	IF	CITATIONS
55	Manifesto for a European Anxiety Disorders Research Network. <i>European Neuropsychopharmacology</i> , 2010, 20, 426-432.	0.3	21
56	Drug-drug interactions in general hospital and psychiatric hospital in-patients prescribed psychotropic medications. <i>International Journal of Psychiatry in Clinical Practice</i> , 2010, 14, 212-219.	1.2	10
57	Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants. <i>Journal of Psychopharmacology</i> , 2010, 24, 709-716.	2.0	25
58	Emotional symptoms in children: The effect of maternal depression, life events, and COMT genotype. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009, 150B, 209-218.	1.1	21
59	Cardiac slowing and acute tryptophan depletion: a comment on the paper by van der Veen et al.. <i>Psychopharmacology</i> , 2009, 203, 831-833.	1.5	1
60	Antidepressant-induced jitteriness/anxiety syndrome: systematic review. <i>British Journal of Psychiatry</i> , 2009, 194, 483-490.	1.7	160
61	Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: An [11C]diprenorphine PET study. <i>European Neuropsychopharmacology</i> , 2009, 19, 740-748.	0.3	61
62	Is the association of hypertension and panic disorder explained by clustering of autonomic panic symptoms in hypertensive patients?. <i>Journal of Affective Disorders</i> , 2008, 111, 344-350.	2.0	9
63	Chapter 5.1 Phenomenology of anxiety disorders. <i>Handbook of Behavioral Neuroscience</i> , 2008, , 365-393.	0.7	8
64	PRN prescribing in psychiatric inpatients - potential for pharmacokinetic drug interactions. <i>Journal of Psychopharmacology</i> , 2007, 21, 153-160.	2.0	36
65	Panic and hypertension: brothers in arms through 5-HT?. <i>Journal of Psychopharmacology</i> , 2007, 21, 563-566.	2.0	26
66	Pharmacokinetics for psychiatrists. <i>Psychiatry (Abingdon, England)</i> , 2007, 6, 268-272.	0.2	1
67	Depleting Serotonin Enhances Both Cardiovascular and Psychological Stress Reactivity in Recovered Patients With Anxiety Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 414-418.	0.7	48
68	IS THERE COGNITIVE IMPAIRMENT IN CLINICALLY "HEALTHY" ABSTINENT ALCOHOL DEPENDENCE?. <i>Alcohol and Alcoholism</i> , 2005, 40, 498-503.	0.9	92
69	Treatment of anxiety and depressive disorders in patients with cardiovascular disease. <i>BMJ: British Medical Journal</i> , 2004, 328, 939-943.	2.4	46
70	Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 464-472.	1.1	64
71	Pharmacokinetics for psychiatrists. <i>Psychiatry (Abingdon, England)</i> , 2004, 3, 5-9.	0.2	1
72	No Evidence That Panic Attacks Are Associated With the White Coat Effect in Hypertension. <i>Journal of Clinical Hypertension</i> , 2003, 5, 145-152.	1.0	11

#	ARTICLE	IF	CITATIONS
73	Addiction. British Medical Bulletin, 2003, 65, 209-222.	2.7	44
74	Drug Intolerance Due to Nonspecific Adverse Effects Related to Psychiatric Morbidity in Hypertensive Patients. Archives of Internal Medicine, 2003, 163, 592.	4.3	43
75	Psychiatric aspects of multiple drug intolerance. American Journal of Hypertension, 2001, 14, A113.	1.0	1
76	Association of panic disorder and panic attacks with hypertension. American Journal of Medicine, 1999, 107, 310-316.	0.6	101
77	Panic disorder, anxiety and depression in resistant hypertension - a caseâ€“control study. Journal of Hypertension, 1997, 15, 1077-1082.	0.3	39
78	Antidepressants versus placebo for panic disorder in adults. The Cochrane Library, 0, , .	1.5	6
79	Benzodiazepines versus placebo for panic disorder in adults. The Cochrane Library, 0, , .	1.5	7
80	Pharmacological treatments in panic disorder in adults: a network meta-analysis. The Cochrane Library, 0, , .	1.5	2